{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Serous+Adenocarcinoma+of+Ovary", "query": { "condition": "Serous Adenocarcinoma of Ovary" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Serous+Adenocarcinoma+of+Ovary&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:54:06.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06494150", "title": "Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Grade Ovarian Serous Adenocarcinoma" ], "interventions": [ { "name": "nab-Sirolimus", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2024-12-26", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06494150" }, { "nct_id": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Mesothelioma, Malignant", "Mesothelioma; Pleura", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Cholangiocarcinoma", "Cholangiocarcinoma Recurrent", "Ovarian Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "High Grade Ovarian Serous Adenocarcinoma" ], "interventions": [ { "name": "gavo-cel", "type": "BIOLOGICAL" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TCR2 Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2019-04-15", "completion_date": "2028-11-02", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 10, "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907852" }, { "nct_id": "NCT05527184", "title": "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "High Grade Serous Adenocarcinoma of Ovary", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cervical Cancer" ], "interventions": [ { "name": "IMGN151", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 256, "start_date": "2023-01-11", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05527184" }, { "nct_id": "NCT03641287", "title": "The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Ovarian Brenner Tumor", "Ovarian Adenocarcinoma", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Transitional Cell Carcinoma" ], "interventions": [ { "name": "Exercise Counseling", "type": "OTHER" }, { "name": "Aerobic Exercise", "type": "OTHER" }, { "name": "Physiological Support", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 64, "start_date": "2018-12-05", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03641287" }, { "nct_id": "NCT01074411", "title": "Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2010-04-05", "completion_date": "2018-01-27", "has_results": false, "last_update_posted_date": "2019-08-09", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 14, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Iowa City, Iowa + 9 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074411" }, { "nct_id": "NCT05074472", "title": "A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Pancreatic Ductal; Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Biliary Cancer Metastatic", "Ovarian Serous Cystadenocarcinoma" ], "interventions": [ { "name": "ZB131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ZielBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-01-14", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05074472" }, { "nct_id": "NCT01167712", "title": "Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinofibroma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 692, "start_date": "2010-09-27", "completion_date": "2026-07-02", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 559, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167712" }, { "nct_id": "NCT02068794", "title": "MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mesenchymal Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Single Photon Tomography and Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-04-25", "completion_date": "2026-09-01", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068794" }, { "nct_id": "NCT05538624", "title": "A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasm, Ovarian", "Fallopian Tube Cancer", "Primary Peritoneal Cavity Cancer", "Adenocarcinoma Ovary", "Serous Adenocarcinoma of Ovary", "Serous Adenocarcinoma of Primary Peritoneum", "Primary Peritoneal Carcinoma", "High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "AVB-001 (Dose Escalation Phase)", "type": "DRUG" }, { "name": "AVB-001 (Dose Expansion Phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenge Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2022-12-09", "completion_date": "2024-04-10", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 5, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538624" }, { "nct_id": "NCT05446298", "title": "ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "High Grade Serous Adenocarcinoma of Ovary", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer" ], "interventions": [ { "name": "ONC-392", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2022-12-22", "completion_date": "2026-08-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T07:54:06.521Z", "location_count": 21, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05446298" } ] }